Defence Therapeutics is pleased to announce that notices of allowance have been issued by the Japanese and Israeli Patent Offices for patent application no. 2018-568469.
Defence Therapeutics Inc., a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and drug delivery technologies, including antibody-drug conjugates.
The allowance of these new patents covers conjugated compounds that permit the delivery of antibodies to the nucleus through the Company’s proprietary technology AccumTM. AccumTM further consolidates the Company’s patent portfolio on its solution for the precision delivery method for improved intracellular antibody-drug conjugate routing. Overcoming problematic cell recycling and rejection patterns, Accum™ enables antibody-drug conjugates to control intracellular delivery of chemotherapeutic drugs, resulting in superior preclinical anti-tumour activity. By increasing the tumour targeting specificity – due to increased drug accumulation – non-specific toxicity in healthy cells is greatly reduced.
“The Japan and Israel patents constitute an important milestone in protecting and expanding the commercial potential of AccumTM directly related to our antibody-drug conjugate programme. Defence is expecting pending key studies results in the near term and will report as they become available. Defence’s commitment to protecting the Company’s AccumTM technology platform innovation is crucial as its antibody-drug conjugate development expands. antibody-conjugate interest continues to increase worldwide being that antibody-drug conjugates are applied in oncology and is advancing rapidly”, says Mr Plouffe, the CEO of Defence Therapeutics.
Huge growth predicted for the antibody-drug conjugate market
According to Precedence Research Predicts, the global oncology market is expected to be worth around US$ 536.01 billion by 2029 compared to USD 286.04 billion in 2021, growing at a CAGR of 8.2% from 2021 to 2030. Oncology is a branch of medicine that deals with cancer prevention, diagnosis, and treatment. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, and nearly one in six deaths. Rising concern about cancer patients is one of the major factors driving the oncology market.
The global antibody-drug conjugate market is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4% during the forecast period, according to a recent 2022 report by Grand View Research Inc. The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive market growth during the forecast period.
About Defence:
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next-generation vaccines and antibody-drug conjugate products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or antibody-drug conjugates in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illnesses such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
